MediPost has developed a next-generation culture method that can improve the stem cell disease treatment effect and production efficiency, and has obtained a patent in China, the company said Wednesday.

The name of this patent is “method to culture mesenchymal stem cells,” and the new invention relates to the way to culture stem cells that have improved proliferation, viability, recovery, aging-suppressing ability, and immunosuppressive ability.

MediPost_{메디포스트} is also using this patented technology to cultivate mesenchymal stem cells it is studying for research, and plans to apply it to the new pipeline.

Mesenchymal stem cells, or MSCs, are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells which give rise to marrow adipose tissue).

In particular, this culture technology is being applied to the development of a “treatment-type degenerative arthritis treatment drug,” which is being developed for application to clinical trials next year.

MediPost acquired patents for this technology in Korea in 2015 and the U.S. in 2017.

"By acquiring the patent, we have secured the base technology to mass-produce mesenchymal stem cells with high efficacy,” a company official said.